0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover402.90%IV-147.52%PremiumAug 16, 2024Expiry Date4.47Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6244Delta0.1183Gamma0.62Leverage Ratio-0.0236Theta-0.0036Rho-0.39Eff Leverage0.0030Vega
Acumen Pharmaceuticals Stock Discussion
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and online ...
NEWS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Sabirnetug demonstrated a favorable safety profile with low incidence of ARIA-E in early AD participants.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma bio...
slowly moving up
No comment yet